Survival Benefit for Early Initiation of Hormone Ablation Therapy in Patients who Fail Definitive XRT for Prostate Cancer (ACP)
Ryan Smith, MD
University of Pennsylvania Cancer Center
Last Modified: November 4, 2001
Presenter: T.C. Tenenholz Affiliation: Medical College of Virginia
There is a dispute over the timing of starting hormones after biochemical failure. This study was initiated to determine when the benefits of hormonal ablation outweighs its potential morbidity.
Materials and Methods
Retrospective study of 931 patients who recieved XRT (635 with curative intent)
394 patients were controlled by XRT, with 241 having biochemical failure (PSA > 1mg/dl). All biochemical failures had metastatic workup upon diagnosis of failure.
Hormonal initiation was done at the discretion of the clinician with no formal policy.
Primary endpoints were OS, DSS, Duration of hormonal control
Hormones had statistically significant improvement in OS and DSS if PSA at time of initiation was <15 ng/ml or PSA doubling time (DT) was > 7 months (OS=70.8%, DSS=86.4% at 5 years).
No additional benefit was seen if hormones were initiated with PSA <10 ng/dl or DT >12 mo.
OS, DSS was much better in patients who were started on hormones with PSA < 15 ng/dl and DT >7 months
DT and PSA were best predictors of OS and DSS
These data support the concept that patients will benefit more from hormonal ablation before the development of metastatic disease or a heavy tumor burden.
Patients with biochemical failure and a high PSA or short DT have a poor outcome, similar to metastatic disease
This has led to an institutional policy of initiating horomes when a patient's PSA level is >10 ng/ml or has a PSA doubling time of < 1 year
The timing in the initiation of hormones after biochemical failure is a topic of debate in the radiation oncology literature. Many have advocated early initiation with claims that it extends the DFS and symptomatic free survival. These data presented seem to support this conclusion. This has led to guidelines of initiating hormonal ablation prior to the development of metastatic disease or heavy tumore burden as evidenced by large PSA.
From this study, it seems as though the longer time until hormones are initiated, the worse patients do, both in terms of overall survival and disease free survival. However, how it affects the actual history of disease is not known. This needs to be investigated in a prospective study.
Oct 4, 2013 - For men with intermediate-risk prostate cancer, long-term hormonal therapy offers no benefit over short-term hormonal therapy, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 22 to 25 in Atlanta.